Health care providers say they are developing anti-disease medicines for people suffering from diarrhea and who are struggling with the symptoms of the disease.
The anti-diabetic drug is being developed by Boston-based BioViva Inc, which also developed the first anti-nausea drug.
“I have been working on the anti-chronic pain and nausea medicines for over 10 years now,” said Dr. Jennifer Janssens, who oversees the Bioviva clinical research and development team.
Janssensen is one of the lead developers of the drug, which is currently in clinical trials.
It was developed in partnership with Boston University, the University of Massachusetts, the National Institutes of Health and the Massachusetts Institute of Technology.
It works by blocking the activity of the enzyme responsible for producing and releasing the hormone pancreas-stimulating hormone, or GHB.
For some people, the drug can prevent the production of the hormone.
In some cases, however, it can cause side effects that can be severe.
In its clinical trials, the anti diabetics drug has been shown to reduce the incidence of colitis, diarrhea, and nausea in patients with colitis who are suffering from a severe infection, according to Biovavac.
Jansson and her team have tested the drug on mice with a number of side effects, including:•A high body temperature•Dizziness and tingling in the face•Pain in the mouth and feet•Nausea and vomiting•Difficulty swallowing•Reduced appetite•Confusion, dizziness, and anxietyJanssen said the drug will also help people who have an allergic reaction to pancreases-stimulant, or insulin, that can trigger diarrhea.
The Drug Enforcement Administration has asked the Food and Drug Administration to approve the anti diabetes drug, according the Associated Press.
It’s not yet known how the drug is supposed to be used in patients who don’t have a serious disease.
Jabsens said Biovava is developing the drug for its own use and has no plans to make it available for the general public.
Biovavavac is also developing a different drug called a cyclic immunosuppressant called CIPA.
Both drugs are approved for treating people with multiple sclerosis, amyotrophic lateral sclerosis, multiple sclerosis with or without spasticity, multiple myeloma and neuropathic pain, the FDA said.
Japsens said she is excited about the development of anti-inflammatory drugs, such as COVID-19 drugs, for people with Crohn’s disease, which affects more than 200 million Americans.
But, she said, Crohn disease is an extremely complicated disease and people have been prescribed many different drugs to treat it.
“We know there are some of those things that work, but there are others that don’t,” Janssen told News24.
Jaksens said people who need anti-inflammatories should seek out the Biova products, but they can’t use them without first getting the drug.
“The idea is to get the drug in the clinic and give it to a patient, so they don’t need to take any of these other medications to control their symptoms,” Jaksens told News 24.